Expand ABBV Menu
ABBV MENU

ABBV Latest Press Releases

-- February 7, 2025 --

U.S. FDA Approves EMBLAVEO (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options PRNewswire 1:28 PM

-- February 6, 2025 --

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle Campaign PRNewswire 8:05 AM

-- February 5, 2025 --

Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons PRNewswire 9:00 AM

-- January 31, 2025 --

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results PRNewswire 7:36 AM

-- January 29, 2025 --

Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans PRNewswire 4:00 AM

-- January 24, 2025 --

Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025 PRNewswire 4:00 AM

-- January 23, 2025 --

AbbVie Completes Acquisition of Nimble Therapeutics PRNewswire 9:17 AM
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology PRNewswire 9:00 AM

-- January 13, 2025 --

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PRNewswire 9:05 AM
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PRNewswire 9:00 AM
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology Business Wire 9:00 AM
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PRNewswire 8:31 AM

-- January 9, 2025 --

AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRNewswire 8:00 AM

-- January 7, 2025 --

CoolMonth is Back With Deals on CoolSculpting Elite by Allergan Aesthetics PRNewswire 8:00 AM

-- January 3, 2025 --

AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call PRNewswire 8:00 AM

-- December 26, 2024 --

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook Globe Newswire 9:00 AM

-- December 13, 2024 --

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline PRNewswire 9:15 AM

-- December 11, 2024 --

AbbVie Completes Acquisition of Aliada Therapeutics PRNewswire 9:15 AM

-- December 9, 2024 --

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma PRNewswire 12:00 PM
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease PRNewswire 8:00 AM

-- December 8, 2024 --

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients PRNewswire 3:00 PM

-- December 7, 2024 --

Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PRNewswire 7:00 PM

-- December 2, 2024 --

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 Business Wire 7:00 AM

-- November 25, 2024 --

AbbVie to Present at Citi's 2024 Global Healthcare Conference PRNewswire 8:00 AM

-- November 18, 2024 --

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products PRNewswire 9:00 AM
AbbVie Receives European Commission Approval of ELAHERE (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer PRNewswire 1:00 AM

-- November 14, 2024 --

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations PRNewswire 8:15 AM

-- November 11, 2024 --

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia PRNewswire 8:30 AM

-- November 7, 2024 --

Allergan Aesthetics Celebrates Annual BOTOX Cosmetic (onabotulinumtoxinA) Day PRNewswire 8:00 AM

-- November 5, 2024 --

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer Business Wire 7:05 AM
Seaport Therapeutics Names Lauren White as Chief Financial Officer Business Wire 7:00 AM

-- October 31, 2024 --

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics Globe Newswire 8:00 AM
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics PRNewswire 8:00 AM

-- October 30, 2024 --

AbbVie Reports Third-Quarter 2024 Financial Results PRNewswire 7:38 AM

-- October 29, 2024 --

SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM PRNewswire 8:00 AM

-- October 28, 2024 --

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline PRNewswire 8:00 AM

-- October 24, 2024 --

AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions PRNewswire 11:30 AM

-- October 18, 2024 --

BOTOX Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) PRNewswire 7:45 PM

-- October 17, 2024 --

U.S. FDA Approves VYALEV (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease PRNewswire 8:00 AM

-- October 16, 2024 --

Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception PRNewswire 8:00 AM

-- October 4, 2024 --

Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM PRNewswire 9:00 AM

-- October 2, 2024 --

Available Nationwide: JUVDERM VOLUMA XC for Moderate to Severe Temple Hollowing PRNewswire 8:01 AM

-- October 1, 2024 --

AbbVie to Host Third-Quarter 2024 Earnings Conference Call PRNewswire 8:00 AM

-- September 27, 2024 --

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer PRNewswire 12:13 PM

-- September 26, 2024 --

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease PRNewswire 8:00 AM

-- September 25, 2024 --

New Analysis Demonstrates the Efficacy of RINVOQ (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement PRNewswire 7:00 AM

-- September 24, 2024 --

Empowering Women Entrepreneurs: 2024 BOTOX (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns PRNewswire 8:00 AM

-- September 20, 2024 --

AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE) for the Treatment of Certain Adult Ovarian Cancer PRNewswire 7:33 AM

-- September 11, 2024 --

Allergan Aesthetics Launches BOTOX Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China PRNewswire 8:30 AM

-- September 9, 2024 --

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs PRNewswire 9:00 AM